{
    "clinical_study": {
        "@rank": "131196", 
        "arm_group": [
            {
                "arm_group_label": "USL261", 
                "arm_group_type": "Experimental", 
                "description": "5 mg intranasal midazolam"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "intranasal placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared\n      with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased\n      seizure activity."
        }, 
        "brief_title": "Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU", 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has been admitted to the institution's EMU for seizure characterization or\n             pre-surgical evaluation, or such admission is planned within 28 days\n\n          -  Subject body weight is \u2265 40 kg to \u2264 125 kg (inclusive)\n\n          -  Subject has an established diagnosis of partial or generalized epilepsy\n\n        Exclusion Criteria:\n\n          -  Subject has history of status epilepticus in the 6 months prior to Screening\n\n          -  Subject has a progressive neurological disorder such as brain tumor, demyelinating\n             disease, or degenerative central nervous system (CNS)disease that is likely to\n             progress in the next 12 months\n\n          -  Subject has respiratory failure (or is at risk for respiratory failure) or other\n             severe cardiorespiratory disease with New York Heart Association Class III or IV\n             functional status, or requires supplemental oxygen\n\n          -  Subject has acute narrow-angle glaucoma\n\n          -  Subject is receiving chronic benzodiazepine treatment (defined as an average of \u2265 4\n             administrations per week) and cannot safely withdraw from such treatment within the\n             washout period prior to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999777", 
            "org_study_id": "USL261-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "USL261", 
                "intervention_name": "USL261", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Epilepsy", 
            "seizure clusters", 
            "acute repetitive seizures", 
            "rescue treatment"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tuscon", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edison", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Temple", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)", 
        "overall_contact": {
            "last_name": "Yolonda Scales", 
            "phone": "1-800-908-6097"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The difference between the USL261- and placebo-treated groups in the proportion of subjects that are seizure-free (no clinically observable seizures) during the Treatment Phase", 
            "measure": "Proportion of subjects that are seizure-free", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to first seizure following treatment (TFSFT)", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "source": "Upsher-Smith Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Upsher-Smith Laboratories", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}